The first patient has been dosed with PMCC-COE-KMA, an investigational CAR T-cell therapy being developed by Peter MacCallum Cancer Centre’s Centre of Excellence in Cellular Immunotherapy (CoE) and licensed by Australian biotechnology company HaemaLogiX. The KOALA trial will evaluate the safety and efficacy of PMCC-COE-KMA in patients… Read More
A UK-led clinical trial has opened at The Christie NHS Foundation Trust in Manchester to test a new drug that could make immunotherapy safer and more accessible for patients with multiple myeloma. The trial, called TOPICAL, is led by The Christie NHS Foundation Trust and will take… Read More
Healx has commenced its Phase I/II dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310 in adolescents and adults with relapsed, refractory sarcoma, with a focus on osteosarcoma. HLX-4310 is an investigational oral combination of a class I selective HDAC inhibitor and an… Read More
Kelsey Jakee, Senior Director, Portfolio Strategy & Innovation at TransCelerate BioPharma, argues why advances in clinical R&D won’t solely be dependent on technology. Every… Read More
A new drug that reduces heart muscle thickening could represent a new treatment option for heart disease patients, a study says. The TEMPEST trial, led by researchers at the University of Manchester, tested the drug trientine in 154 adults with hypertrophic cardiomyopathy in a year-long, placebo-controlled study. Read More
Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it. Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More
Compounds derived from ‘magic mushrooms’ could be a potential treatment for anorexia nervosa, a study says. A small pilot trial from the Centre for Psychedelic Research at Imperial College London indicates that psilocybin – the active ingredient in psychedelic ‘magic mushrooms’ – may have potential as a treatment for… Read More
Is the honeymoon period over for GLP-1s or is the market yet to reach its full potential? Diana Turner asks what will differentiate the next generation of these peptide analogues. Glucagon-like peptide-1 (GLP-1)… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More
As DDW launches its new event series Drug Discovery Innovators & Investors, Lu Rahman looks at the challenges and opportunities that exist for both drug… Read More
News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW. This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer. The… Read More
This paid-for advertorial by Sampled appeared in DDW Volume 27 – Issue 3, Summer 2026. Biological samples are critical across the clinical trial lifecycle, providing the raw material for understanding disease mechanisms, tracking biomarker dynamics, and evaluating… Read More
The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Suzanne Caruso, President of Strategic Intelligence and Clinical & Regulatory at Norstella. Norstella supports drug developers looking to take their treatments from pipeline to patients, finding solutions to complexities… Read More
The US Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) as a treatment for thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterised by inflammation and tissue remodelling around and behind the eyes, which can lead to proptosis, diplopia, pain and vision impairment. Read More
The US Food and Drug Administration (FDA) has granted Dicot Pharma approval to roll out the Phase IIb study of a treatment for erectile dysfunction. The approval follows an Investigational New Drug (IND) Application submitted to the FDA, with the trial evaluating LIB-01 now set to commence in the US. … Read More
